JOINT STATEMENT

Priorities for Eliminating Cervical Cancer as a Public Health Problem in Europe

The Joint Signatories call for all European Union (EU) and WHO/Europe member states to take immediate action towards fulfilling the ambitious goal of eliminating cervical cancer as a public health problem.¹

On 17 November 2020, the WHO formally launched the first-ever global effort to accelerate the elimination of a specific cancer type (1). Cervical cancer is an almost entirely preventable cancer thanks to prophylactic vaccination against human papillomavirus (HPV) and screening and treatment of cervical precancers (2).

Despite the availability of several highly effective tools for preventing and controlling cervical cancer, in 2020 alone, more than 341,000 women worldwide were estimated to have died due to this cancer (3). Within the EU-27 member states,

¹ The WHO global strategy for the elimination of cervical cancer sets a threshold for elimination of an age-adjusted incidence rate of <4 per 100,000 per year.
approximately 33,000 women and their families receive a diagnosis of cervical cancer and 15,000 women lose their lives annually due to this disease with associated social and economic losses to families, communities and economies (4). With an increasing incidence over time (5), the burden of cervical cancer falls disproportionately on women and families in Eastern Europe and economically and socially vulnerable communities within countries. Nevertheless, all countries must take action to improve cervical cancer control.

Considering that almost every life claimed by cervical cancer can be potentially saved by equitable access to safe, evidence-based and effective preventative and treatment strategies, there is no time to lose in striving to achieve the following 2030 cervical cancer elimination targets in Europe:

- 90% of girls fully vaccinated with HPV vaccine by 15 years of age;
- 70% of women screened with a high precision test by 35 and 45 years of age; and
- 90% of women identified with cervical precancer or cancer receive treatment and care (6).

Considering that the recently adopted Europe’s Beating Cancer Plan³ aims to support EU member states in meeting these targets, we the joint signatories urge policymakers across Europe to embrace the opportunity to eliminate cervical cancer as a public health concern, measured by reducing incidence below 4/100,000 per year, by prioritising the following actions using a comprehensive approach that leaves no-one behind:

1. Adopt, communicate and implement evidence-based screening policies
   a. Evidence shows HPV-based screening is the preferred tool for primary screening for cervical cancer in European countries (7,8). Validated HPV testing should be offered according to existing evidence regarding the eligible age groups and screening intervals, with special attention to women living with HIV (9).
   b. Women found to be positive on HPV test require triage to maximise the benefits and minimise the potential harms from unnecessary investigations and treatment. Policies for triaging women should carefully follow

emerging evidence on effective triage algorithms and possible integration of triage biomarkers (10,11).

2. **Ensure that cervical cancer screening is provided within an organised framework**
   a. Cervical cancer screening should be offered to women in the framework of an organised programme. The programme should be comprehensive and have a governance structure for monitoring and evaluation (12). It should be able to identify and invite women eligible for screening, actively discourage the potential for over-screening of women outside of the organised framework and ensure appropriate triage, diagnosis, and treatment, if required.
   b. Organised programmes offer an efficient method for monitoring and assuring the quality of screening and management, and can respond in a timely way to innovations and potential adaptations such as e-health tools required to improve the quality of screening.

3. **Optimise screening coverage, especially in Central and Eastern Europe, intensifying efforts to reach women not responding to the screening invitation**
   a. All women eligible for screening deserve the offer of making an informed choice about participation. Yet too many women, especially those in marginalised settings, face barriers to attend screening services. HPV-based screening offers the benefit of self-collection of samples by the women, which may be a suitable alternative tool for the hard-to-reach women and the preferred approach during the ongoing Covid-19 pandemic (13).
   b. Self-sampling should only be offered within an organised framework and only validated methods should be used. Screening programmes that want to introduce self-sampling should implement pilot studies to define the best delivery method for HPV test as approaches will be very much dependent on the local culture, preference and context (14).

4. **Ensure treatment of the screen detected precancers and cancers**
   a. Screening alone will not be able to prevent cervical cancer unless the screen detected precancers are appropriately treated. Many women with
precancerous cervical lesions can be treated by simple techniques like local surgical excision or ablation.

b. Stage appropriate treatment of every woman detected to have cervical cancer without any delay should be prioritized in every setting. Quality of care must be at a core of cancer management, so women have the best chances for cure and quality of life.

5. Maximise HPV vaccination coverage to reach the 90% target by 2030

a. Large variation exists in HPV vaccination coverage rates across Europe, with low rates (or the absence of a vaccination programme) frequently observed in countries with the highest incidence of cervical cancer (15). The momentum of the explicit support from Europe’s Beating Cancer Plan must be seized to ensure that HPV vaccination is included in the routine vaccination schedule of all countries.

b. Investments are required into health service and implementation research for strategies to reach under-served population groups and increase and maintain confidence in the HPV vaccine following effective practice for addressing vaccine hesitancy.

c. Cross-border initiatives to improve the affordability of HPV vaccines should be pursued, particularly to improve access for middle-income countries.

6. Update the EU guidelines for cervical cancer control, advising on the integration of elimination services with women-centred approaches

a. The initiative to publish an updated edition of EU guidelines for cervical cancer prevention should begin in earnest, if the 2030 targets for cervical cancer elimination are to be met.

b. The guidelines should address the combined area of primary and secondary prevention, recognising the importance of overcoming inequalities of access to quality assured services in the line with all three of the 2030 targets.

c. Full consideration should be given to supporting equitable access through free access of vulnerable groups to health services with integration into universal health coverage approaches.
7. Empowering women and working closely with civil society

a. The goal of eliminating cervical cancer provides us with a much needed positive narrative as the world continues to face the Covid-19 pandemic. Patient and advocacy groups will be vital partners in amplifying this message.

b. Taking action to eliminate cervical cancer provides us with a unique opportunity to re-energise and inspire health professionals by pointing the way to diminish the societal impact of a serious malignant disease. The momentum of the innovations to improve laboratory facilities, information systems and m-Health, as well to improve vaccine confidence, must not be lost.

The Joint Signatories urge that 17 November is, henceforth, recognised and commemorated as the global day for cervical cancer elimination, which is supported by Europe-wide synchronised campaign to maintain the progress towards cervical cancer elimination.

Signatories

Organisations

1. Association of Slovenian Cancer Societies
2. Breakthrough Cancer Research
3. Catalan Institute of Oncology (ICO)
4. Croatian League Against Cancer
5. Catalan Federation Against Cancer (FECEC)
6. Cancer Society of Finland (CSF)
7. Cancer Research UK (CRUK)
8. CPO Piedmont – Screening Unit
9. Danish Cancer Society
10. Dutch Cancer Society (KWF)
11. Emanuele Cancer Research Foundation Malta (ECRF)
12. EuroHealthNet
13. European Oncology Nursing Society (EONS)
15. European Public Health Alliance (EPHA)
16. European Regional and Local Health Authorities (EUREGHA)
17. HPV Prevention and Control Board (HPV Board)
18. International Organization for Migration (IOM)
19. Irish Cancer Society (ICS)
20. Irish Cancer Prevention Network (ICPN)
21. Institute of Oncology Ljubljana
22. Italian Cervical Carcinoma Screening Group (GISCi)
23. League Against Cancer Prague (LPR Prague)
24. League Against Cancer Slovakia (LPR)
25. Lega Italiana Lotta contro i Tumori Milano Monza Brianza
26. Medicines for Europe
27. MEPs Against Cancer Interest Group
28. National Institute of Oncology, Hungary
29. National Institute of Public Health, Romania INSP (NIPH)
30. National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos National Center of Pathology
31. Norwegian Cancer Society
32. Novosanis
33. O Fonds
34. Polish Cancer League (PLWzR)
35. Portuguese League Against Cancer
36. PRESCRIP-TEC Global Health Unit UMCG
37. Programma Mattone Internazionale Salute (ProMIS)
38. RIVER-EU
39. Sciensano
40. Scottish Government, Digital Health and Care Directorate (DHCD)
41. Spanish Association Against Cancer (AECC)
42. Stand up to Cancer Flanders (KotK)
43. Swiss Cancer League
44. Taskforce Nederland HPVkankervrij
45. The Marie Keating Foundation (MKF)
46. The Cyprus Anti-Cancer Society
47. Turkish Association for Cancer Research and Control
48. Union for International Cancer Control (UICC)
49. Vaccines Today
50. Vienna Vaccine Safety Initiative
51. World Cancer Research Fund International (WCRF International)
<table>
<thead>
<tr>
<th></th>
<th>Individual</th>
</tr>
</thead>
<tbody>
<tr>
<td>52.</td>
<td>MEP Alex Agius Saliba (S&amp;D, Malta)</td>
</tr>
<tr>
<td>53.</td>
<td>MEP Biljana Borzan (S&amp;D, Croatia)</td>
</tr>
<tr>
<td>54.</td>
<td>MEP Brando Benifei (S&amp;D, Italy)</td>
</tr>
<tr>
<td>55.</td>
<td>MEP Claudia Gamon (RE, Austria)</td>
</tr>
<tr>
<td>56.</td>
<td>MEP Chrysoula Zacharopoulou (RE, France)</td>
</tr>
<tr>
<td>57.</td>
<td>MEP Fabio Massimo Castaldo (non-attached, Italy)</td>
</tr>
<tr>
<td>58.</td>
<td>MEP Frances Fitzgerald (EPP, Ireland)</td>
</tr>
<tr>
<td>59.</td>
<td>MEP Gianna Gancia (ID, Italy)</td>
</tr>
<tr>
<td>60.</td>
<td>MEP Hilde Vautmans (RE, Belgium)</td>
</tr>
<tr>
<td>61.</td>
<td>MEP Jordi Cañas (RE, Spain)</td>
</tr>
<tr>
<td>62.</td>
<td>MEP Olivier Chastel (RE, Belgium)</td>
</tr>
<tr>
<td>63.</td>
<td>MEP Sara Cerdas (S&amp;D, Portugal)</td>
</tr>
<tr>
<td>64.</td>
<td>MEP Seán Kelly (EPP, Ireland)</td>
</tr>
<tr>
<td>65.</td>
<td>MEP Sirpa Pietikäinen (EPP, Finland)</td>
</tr>
<tr>
<td>66.</td>
<td>MEP Tilly Metz (Greens/EFA, Luxembourg)</td>
</tr>
<tr>
<td>67.</td>
<td>MEP Véronique Trillet-Lenoir (RE, France)</td>
</tr>
<tr>
<td>68.</td>
<td>Prof Dr Steven Van Gucht, Head of Viral Diseases, Sciensano</td>
</tr>
<tr>
<td>69.</td>
<td>Prof Guido Van Hal, Professor Social Epidemiology, Antwerpen University</td>
</tr>
<tr>
<td>70.</td>
<td>Prof Jean-Yves Blay, President, Unicancer</td>
</tr>
<tr>
<td>71.</td>
<td>Prof Dr Joakim Dillner, Scientific Director, Karolinska University Hospital, Head of Unit,</td>
</tr>
<tr>
<td></td>
<td>Center for Cervical Cancer Prevention</td>
</tr>
<tr>
<td>72.</td>
<td>Dr Paolo Giorgi Rossi, Director, Epidemiology and Risk Communication Interagency Service, AUSL</td>
</tr>
<tr>
<td></td>
<td>Reggio Emilia</td>
</tr>
<tr>
<td>73.</td>
<td>Dr Livia Giordano, Director, Screening Unit , CPO Piedmont – AOU Città della Salute e</td>
</tr>
<tr>
<td></td>
<td>della Scienza</td>
</tr>
<tr>
<td>74.</td>
<td>Dr Paola Armaroli, Epidemiologist, Screening Unit, CPO Piedmont – AOU Città della Salute e</td>
</tr>
<tr>
<td></td>
<td>della Scienza</td>
</tr>
<tr>
<td>75.</td>
<td>Dr Mercè Marzo-Castillejo, General Practitioner Researcher, Unitat de Suport a la Recerca</td>
</tr>
<tr>
<td></td>
<td>(USR) Costa de Ponent</td>
</tr>
<tr>
<td>76.</td>
<td>Dr Vítor Rodrigues, Associate Professor, University of Coimbra</td>
</tr>
<tr>
<td>77.</td>
<td>Dr Carmen Ungurean, Cancer Screening Coordinator, National Institute of Public Health,</td>
</tr>
<tr>
<td></td>
<td>Romania</td>
</tr>
<tr>
<td>78.</td>
<td>Dr Janine de Zeeuw, Researcher, The University Medical Center Groningen (UMCG)</td>
</tr>
<tr>
<td>79.</td>
<td>Isabel Portillo, Cancer Screening Coordinator, The Basque Health Service</td>
</tr>
<tr>
<td>80.</td>
<td>Tine Jerman, Data Analyst, Institute of Oncology Ljubljana</td>
</tr>
<tr>
<td>81.</td>
<td>Dr Manges Thorat, Deputy Director (Clinical) – Cancer Prevention Trials Unit (KHP), King’s</td>
</tr>
<tr>
<td></td>
<td>College London</td>
</tr>
<tr>
<td>82.</td>
<td>Dr Sue Sherman, Lecturer in Psychology, Keele University</td>
</tr>
<tr>
<td>83.</td>
<td>Dr Francesca Maria Carozzi, Biologist, University of Florence</td>
</tr>
<tr>
<td>84.</td>
<td>Dr Giuseppe La Torre, Professor, Department of Public Health and Infectious Diseases,</td>
</tr>
<tr>
<td></td>
<td>Sapienza University of Rome</td>
</tr>
<tr>
<td>85.</td>
<td>Dr Severien Van Keer, Postdoctoral researcher, University of Antwerp</td>
</tr>
</tbody>
</table>
86. Sigita Bagdoniene, NCP Health, Research Council of Lithuania
87. Dr Francesco Chierigo, Urology Resident, IRCCS Polyclinic IRCCS Hospital San Martino, Genova, Italy
88. Dr Janet Raycheva, Medical Oncology Resident and CancerCare.bg’s Content manager
89. Dr Amil Družić, MD, Radiation Oncology Resident & ECL Youth Ambassador for the European Code Against Cancer for Bosnia and Herzegovina
90. Dr Meritxell Mallafré-Larrosa, Public Health Agency of Catalonia
91. Mashkur Abdulhamid Isa, MPH Student, University of Sheffield
92. Christos Tsagkaris, Medical Student, University of Crete
93. Elif Tufan, Medical Student, Marmara University
94. İkbal Kayabaş, Medical Student, Marmara University
95. Maša Davidović, PhD-candidate, Swiss Tropical and Public Health Institute
96. Stefanie Veraghtert, Founder & CEO, The Big C.
97. Karmen Korda, Junior Researcher, Croatian Institute of Public Health
98. Helena Vučković, ECL Youth Ambassador for the European Code Against Cancer for Croatia
99. Iuliana Stratan, ECL Youth Ambassador for the European Code Against Cancer for Moldova
100. Bianca Wolf, ECL Youth Ambassador for the European Code Against Cancer for Austria
101. Zoë Verloo, ECL Youth Ambassador for the European Code Against Cancer for Belgium
102. Gizem Acar, ECL Youth Ambassador for the European Code Against Cancer for Turkey
103. Nadezda Majdalani, ECL Youth Ambassador for the European Code Against Cancer for Bulgaria
104. Shukurgeldi Myradov, ECL Youth Ambassador for the European Code Against Cancer for Turkmenistan
105. Dr Miljana Stojanovska, ECL Youth Ambassador for the European Code Against Cancer for North Macedonia
106. Krassimira Zaykova, ECL Youth Ambassador for the European Code Against Cancer for Bulgaria
107. Dr Dino Mehic, ECL Youth Ambassador for the European Code Against Cancer for Austria
108. Lydia van Geloven, Director, Credo Business Generator
109. Patricia Pinto, Psychologist, Portuguese League Against Cancer
References


